Sees FY23 net product revenue about $159M. The company had unaudited cash, cash equivalents, restricted cash and investments of approximately $351M as of December 31, 2023. The company is expecting to become cash flow positive on a go forward basis in the second half of 2024. As previously announced, the company initiated a robust strategic review at the end of June 2023 and is continuing to review all strategic options for the company, which include a variety of possibilities including, but not limited to, a potential sale, merger, or other strategic transaction. At this time, there are no further updates on the matter, other than that the process is continuing. The Board of Directors and the Executive Leadership team remain committed to running a fulsome process that reflects the best interests of the company, our shareholders, and other key stakeholders, including our patients, healthcare providers, and our employees.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AUPH:
- Aurinia Pharmaceuticals submits IND application to FDA for AUR200
- Aurinia Pharmaceuticals put volume heavy and directionally bearish
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
- Aurinia strength may be related to Gilead suspicion, says Gordon Haskett
- Aurinia Pharmaceuticals partner Otsuka files NDA in Japan for Lupkynis
